Clinical trials: Obesity and Overweight
Obesity
A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus
This is a Phase 1/2a double-blind dose-escalating study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of ARO-INHBE in adult participants with obesity (in Part…
- Trial name
- NCT06700538
- Testing
- ARO-INHBE, Tirzepatide
- Where
- 15 sites in Australia, Canada and 2 more
- Volunteers
- 190 people
- Sponsor
- Arrowhead Pharmaceuticals
Obesity, Adiposity
Endoscopic Gastric Mucosal Ablation as a Primary Obesity Therapy
This study is intended to investigate safety and feasibility of a new weight loss technique called endoscopic Gastric Mucosal Ablation (GMA) that does not require surgery, but can be achieved using an endoscopic procedure.
- Trial name
- COMET (NCT05486338)
- Testing
- Hybrid Argon Plasma Coagulation (HAPC)
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Erbe Elektromedizin GmbH
Bardet Biedl Syndrome (BBS), Alström Syndrome (AS)
Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity
This pivotal, phase 3 study is designed to confirm the efficacy and safety of setmelanotide, a potent melanocortin receptor type 4 (MC4R) agonist, for the treatment of obesity and hyperphagia in participants with Bardet Biedl…
- Trial name
- NCT03746522
- Testing
- Setmelanotide
- Where
- 12 sites in United States, Canada and 4 more
- Volunteers
- 52 people
- Sponsor
- Rhythm Pharmaceuticals, Inc.
Obesity
The ValenTx Endo Bypass System in Obese Subjects
The purpose of this study is to collect clinical data to support the use of the ValenTx Endo Bypass System to improve weight loss and the resolution of comorbidities in obese subjects.
- Trial name
- NCT02954003
- Testing
- Endo Bypass System
- Where
- 3 sites in Canada, Mexico
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- ValenTx, Inc.
Healthy, Obesity
A Study to Test How Well Different Doses of BI 3034701 Are Tolerated by Japanese Healthy People and Japanese People With Obesity or Overweight
Part 1: To investigate safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of BI 3034701 in Japanese male and female participants with body mass index (BMI) ≥27.0 kg/m² or more following subcutaneous…
- Trial name
- NCT07693231
- Testing
- BI 3034701
- Where
- 3 sites in Japan
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Obesity
Vestibular Stimulation to Trigger Adipose Loss (VeSTAL) Clinical Trial
A randomized, double blind sham controlled clinical trial to evaluate the efficacy of vestibular nerve stimulation (VeNS), combined with a lifestyle modification program, compared to a sham control and a lifestyle modification…
- Trial name
- VeSTAL (NCT03640286)
- Testing
- VeSTAL
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 241 people, healthy volunteers welcome
- Sponsor
- Neurovalens Ltd.
Obesity
Pharmacokinetic Comparison of Multiple Formulations of Topiramate and Phentermine in Obese Adults
The primary objective of this study is to describe the single- and multiple-dose pharmacokinetic profiles of two novel formulations of topiramate and commercially available immediate release topiramate, all dosed with immediate…
- Trial name
- NCT00518466
- Testing
- topiramate, phentermine
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- VIVUS LLC
Diabetes Mellitus, Type 2
Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes
The main objective of this trial is to evaluate whether maridebart cafraglutide is non-inferior to semaglutide in improving glycemic control in participants with type 2 diabetes (T2D) who are receiving metformin treatment, with…
- Trial name
- MARITIME-T2D-3 (NCT07866066)
- Testing
- Maridebart cafraglutide, Semaglutide
- Volunteers
- 1,300 people
- Sponsor
- Amgen
Obesity Hypoventilation Syndrome
Toffee Full Face and Toffee Nasal Mask Evaluation in Obesity Hypoventilation Syndrome (NZ)
This investigation is to evaluate the performance, comfort and ease of use of the Toffee full face and toffee nasal mask masks amongst Obesity Hypoventilation Syndrome (OHS) patients in an overnight study.
- Trial name
- NCT02486380
- Testing
- Toffee full face mask/toffee nasal mask
- Where
- New Zealand
- Volunteers
- 4 people
- Sponsor
- Fisher and Paykel Healthcare
Obesity or Overweight, Diabetes Mellitus, Type 2
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment
- Trial name
- SELENE 2 (NCT07784270)
- Testing
- Lenbelintide
- Where
- 230 sites in United States, Argentina and 14 more
- Volunteers
- 1,500 people
- Sponsor
- AstraZeneca
Overweight and Obesity
Effect of ANACA3 Slimming Gel on Loss of Abdominal and Thigh Circumferences in Healthy Volunteers
Overweight and obesity is defined, according to the World Health Organization (WHO), by abnormal or excessive accumulation of adipose or fatty tissue that may be harmful to health.
- Trial name
- NCT03685656
- Testing
- Slimming gel
- Where
- France
- Volunteers
- 208 people, healthy volunteers welcome
- Sponsor
- Nutravalia
Obesity
Endoscopic Suturing System for Tissue Apposition
The objective of this feasibility trial is to evaluate the Ethicon Endo-Surgery Endoscopic Suturing System (ESS) for tissue apposition and reduction of the size of a dilated GJ anastomosis in subjects who are regaining weight…
- Trial name
- NCT00495222
- Testing
- Tissue plication, Endoscopic Suturing System
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Ethicon Endo-Surgery
Obesity
A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight
This study will look at how well semaglutide helps children and teenagers losing weight. This will be tested by comparing the effect on body weight in children and teenagers taking semaglutide in comparison to placebo, a "dummy"…
- Trial name
- STEP Young (NCT05726227)
- Testing
- Semaglutide
- Where
- 56 sites in United States, Austria and 8 more
- Volunteers
- 212 people
- Sponsor
- Novo Nordisk A/S
Overweight and Obesity, Healthy
A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a Glucagon-like Peptide-1 (GLP-1) Agonist
Adult participants with BMI between 22 - 35 kg/m2 will be enrolled and randomized to receive either NG101 (20 mg twice daily [BID]) or placebo for 5 days beginning on Day 1.
- Trial name
- NCT06500429
- Testing
- NG101, Semaglutide Injectable Product
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Neurogastrx, Inc.
Obesity
Clinical Observation of Implementing the MedGem Into a Medical Specialty Practice
Due to common CVD diseases associated from obesity, medical providers are in a position to provide assistance. However, less than 10% of all patients receive any weight loss advice from physicians.
- Trial name
- NCT00489502
- Testing
- Brief Counseling, REE Assessment
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Microlife
Obesity, Overweight or Obesity
A Phase 2b Study to Examine the Safety and Efficacy of Once-Weekly MET097 in Adults With Obesity or Overweight
This study is designed to test how well MET097, an active drug, works to treat individuals with obesity or overweight when compared to placebo. MET097 or placebo will be given to individuals weekly for 28 weeks.
- Trial name
- VESPER-1 (NCT06712836)
- Testing
- MET097
- Where
- 2 sites in United States
- Volunteers
- 239 people
- Sponsor
- Pfizer
Overweight, Obesity
A Study to Compare Two Different Forms of PF-07081532 in Adults Who Are Overweight or Obese
The purpose of this study is to compare the amount of PF-07081532 in blood after taking two different forms of PF-07081532. This study is seeking participants who are at least 18 years of age and are overweight and/or obese.
- Trial name
- NCT05677867
- Testing
- Formulation A (PF-07081532 20 mg plus 60 mg), Formulation B (PF-07081532 80 mg)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obesity and Cardiovascular Risk
Obesity and Cardiovascular Diseases, Cross-sectional Study in Saudi Arabia
The purpose of this research study is to collect information on participants body weight, blood sugar levels, heart related diseases and lifestyle.
- Trial name
- OCCURS (NCT05642533)
- Testing
- No treatment given
- Volunteers
- 1,061 people
- Sponsor
- Novo Nordisk A/S
Healthy Participants
A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants
The purpose of this study is to measure the pharmacokinetics (PK-how the body processes the study drug) of elecoglipron in healthy participants when taken by mouth as different formulations.
- Trial name
- NCT07723833
- Testing
- Elecoglipron Reference Formulation Dose A, Elecoglipron Test formulation 1 Dose A, Elecoglipron Reference Formulation Dose B
- Where
- 2 sites in United States
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Obesity, Weight Loss
Does Use of the Voy Program Improve Weight Loss Percentage and Other Health Outcomes in a Population Already Taking GLP/GIP-1RA Medication?
The aim of the trial is to assess the impact of the Voy Program on weight loss and other health outcomes in an obese population already approved for GLP/GIP-1RA medication.
- Trial name
- VOYAGER (NCT06710587)
- Testing
- Voy Program
- Volunteers
- 470 people
- Sponsor
- Menwell Limited
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.